Effect of bosentan therapy in persistent pulmonary hypertension of the newborn
Background: Persistent pulmonary hypertension of the newborn (PPHN) contributes to neonatal hypoxemia and is associated with a high mortality. Some PPHN patients are unresponsive to inhaled nitric oxide (iNO). Bosentan, an oral endothelin-1 receptor antagonist, reduces pulmonary vascular resistance...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-02-01
|
Series: | Pediatrics and Neonatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957217304102 |